ROSSO-in-praxi: a self-monitoring of blood glucose-structured 12-week lifestyle intervention significantly improves glucometabolic control of patients with type 2 diabetes mellitus.

abstract：BACKGROUND:Lipohypertrophy (LH) is a complication of insulin therapy. We assessed LH prevalence, risk factors, insulin usage, and clinical and health economic effects in China. METHODS:In four cities, 401 adult patients injecting insulin ≥1 year were surveyed for diabetes/insulin injection history and practices, pen n...

journal_title：Diabetes technology & therapeutics

authors： Ji L,Sun Z,Li Q,Qin G,Wei Z,Liu J,Chandran AB,Hirsch LJ

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring is a useful tool for the achievement of improved glucose control in patients with diabetes. We tested the ability of a novel noninvasive continuous glucose monitor to track glucose excursions. METHODS:The novel noninvasive Aprise sensor (Glucon Inc., Boulder, CO) utilizes the p...

journal_title：Diabetes technology & therapeutics

authors： Weiss R,Yegorchikov Y,Shusterman A,Raz I

更新日期：2007-02-01 00:00:00

abstract：BACKGROUND:During the proteomic era, one of the most rapidly growing areas in biomedical research is biomarker discovery, particularly using proteomic technologies. The urinary proteome is known to be a valuable field of study and has become one of the most attractive subdisciplines in clinical proteomics for human dis...

journal_title：Diabetes technology & therapeutics

authors： Riaz S,Alam SS,Srai SK,Skinner V,Riaz A,Akhtar MW

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glyc...

journal_title：Diabetes technology & therapeutics

authors： Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:The management of hyperglycemia in the intensive care unit has been a controversial topic for more than a decade, with target ranges varying from 80-110 mg/dL to <200 mg/dL. Multiple insulin infusion protocols exist, including several computerized protocols, which have attempted to achieve these targets. Imp...

journal_title：Diabetes technology & therapeutics

authors： Marvin MR,Inzucchi SE,Besterman BJ

更新日期：2016-08-01 00:00:00

abstract：:Use of the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in non-diabetic children has revealed many low and high sensor glucose (SG) values, suggesting that the original analytical algorithm (Solutions 2.0) might be overreading glycemic excursions. A revised algorithm (Solutions 3.0) was introduced in ...

journal_title：Diabetes technology & therapeutics

authors： Weinzimer SA,DeLucia MC,Boland EA,Steffen A,Tamborlane WV

更新日期：2003-01-01 00:00:00

abstract：:Continuous glucose monitoring (CGM) systems have been available for more than 15 years by now. However, market uptake is relatively low in most countries; in other words, relatively few patients with diabetes use CGM systems regularly. One major reason for the reluctance of patients to use CGM systems is the costs ass...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L,DeVries JH

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

journal_title：Diabetes technology & therapeutics

authors： Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:Visual disabilities due to diabetes are on the rise, especially in urban areas of developing countries. Proper health planning will need evidence-based information. STUDY DESIGN AND METHODS:We estimated the prevalence and identified the determinants of eye complications among persons with diabetes screened ...

journal_title：Diabetes technology & therapeutics

authors： Vyas U,Khandekar R,Trivedi N,Desai T,Danayak P

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:The aim of this study was to elucidate the characteristics of accuracy of subcutaneous continuous glucose monitoring (SCGM) in the perioperative period for neurosurgical and cardiac surgery patients. METHODS:Forty-five subjects, including healthy volunteers (n = 15), neurosurgical patients (n = 15), and car...

journal_title：Diabetes technology & therapeutics

authors： Sugiyama Y,Wakabayashi R,Urasawa M,Maruyama Y,Shimizu S,Kawamata M

更新日期：2018-10-01 00:00:00

abstract：AIM:Insulin therapy induces remission in subjects with newly diagnosed type 2 diabetes mellitus (T2DM). This study assessed the insulin and C-peptide levels in newly diagnosed T2DM subjects during low-dose insulin therapy. SUBJECTS AND METHODS:Twenty newly diagnosed, drug-naive, T2DM patients without acute or chronic ...

journal_title：Diabetes technology & therapeutics

authors： Bhattacharya S,Ammini AC,Jyotsna V,Gupta N,Dwivedi S

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Weight gain often occurs when insulin therapy is initiated. The long-acting insulin analog insulin detemir has been shown to be effective and well tolerated when used in basal-bolus regimens or as an add-on to oral antidiabetic drugs (OADs) and causes less weight gain than other insulins. The aim of this exp...

journal_title：Diabetes technology & therapeutics

authors： Davies MJ,Derezinski T,Pedersen CB,Clauson P

更新日期：2008-08-01 00:00:00

abstract：BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

journal_title：Diabetes technology & therapeutics

authors： Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

更新日期：2010-08-01 00:00:00

abstract：BACKGROUND:Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes, if not treated. International guidelines recommend screening "all or high-risk women" at the initial prenatal visit, when a fasting plasma glucose (FPG) between 92 and 126 mg/dL is diagnostic for GDM. However, glucose testing ...

journal_title：Diabetes technology & therapeutics

authors： Festa R,Carta M,Ceriello A,Testa R

更新日期：2012-05-01 00:00:00

abstract：:Glucose oxidase has had a central role in previous glucose sensing methods and is key to the development of certain new glucose sensors. The immobilized enzyme is specific for glucose and sufficiently long-lived for many sensor applications, but new glucose sensing applications may place increased demands on the enzym...

journal_title：Diabetes technology & therapeutics

authors： Gough DA,Bremer T

更新日期：2000-10-01 00:00:00

abstract：:The World Wide Web now hosts a multitude of diabetes educational materials in various formats. Of particular interest is the diabetes/insulin tutorial available at the AIDA Website (accessible directly at: www.2aida.info). The tutorial combines textual or "static" information with an interactive diabetes simulator-AID...

journal_title：Diabetes technology & therapeutics

authors： Reed K,Lehmann ED

更新日期：2006-02-01 00:00:00

abstract：:Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

journal_title：Diabetes technology & therapeutics

authors： Levine BJ,Close KL,Gabbay RA

更新日期：2020-01-01 00:00:00

abstract：AIM:To describe the continuous glucose monitoring (CGM) profiles of type 1 diabetes (T1D) offspring in the early neonatal period and its association with maternal intrapartum glucose control. METHODS:A prospective observational study of T1D pregnant women and their neonatal offspring. Women had a CGM sensor inserted 2...

journal_title：Diabetes technology & therapeutics

authors： Stewart ZA,Thomson L,Murphy HR,Beardsall K

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

journal_title：Diabetes technology & therapeutics

authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS:On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and und...

journal_title：Diabetes technology & therapeutics

authors： Bailey TS,Zisser HC,Garg SK

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes. METHODS:This single-center, open-label, single-arm, sequential trial enrolled subjects with ...

journal_title：Diabetes technology & therapeutics

authors： Schwartz S,Vlajnic A

更新日期：2008-10-01 00:00:00

abstract：:Measuring the hemoglobin A(1c) (HbA(1c)) is the standard-of-care method to assess long-term glycemic control of patients with diabetes, describing the average glycemic level. However, the HbA(1c) does not reflect acute fluctuations in glucose levels. Variability of glycemia probably has an impact on the development of...

journal_title：Diabetes technology & therapeutics

authors： Thomas A,Schönauer M,Achermann F,Schnell O,Hanefeld M,Ziegelasch HJ,Mastrototaro J,Heinemann L

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:To protect against ischemia, pressure-induced vasodilation (PIV) causes an increase in skin blood flow. Endothelial dysfunction, which is commonly found in older patients and those with diabetes, and global temperatures can affect the resting blood flow in skin, which may reduce the blood flow during and aft...

journal_title：Diabetes technology & therapeutics

authors： McLellan K,Petrofsky JS,Zimmerman G,Lohman E,Prowse M,Schwab E,Lee S

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:Multicenter long-term studies of predictors for the effectiveness of continuous subcutaneous insulin infusion (CSII) in clinical practice are lacking. We hypothesized that there are substantially greater reductions in hemoglobin A1c (HbA1c) in patients with poor glycemic control and that other predictors may...

journal_title：Diabetes technology & therapeutics

authors： Clements M,Matuleviciene V,Attvall S,Ekelund M,Pivodic A,Dahlqvist S,Fahlén M,Haraldsson B,Lind M

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

journal_title：Diabetes technology & therapeutics

authors： Whitelaw BC,Choudhary P,Hopkins D

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:The recent availability of a continuous glucose monitor offers the opportunity to match the demands of intensive diabetes management with a period of equally intensive blood glucose monitoring. The present study evaluates the performance of the MiniMed continuous glucose monitoring system (CGMS) in patients ...

journal_title：Diabetes technology & therapeutics

authors： Gross TM,Bode BW,Einhorn D,Kayne DM,Reed JH,White NH,Mastrototaro JJ

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:The Ascensia CONTOUR System (Bayer HealthCare LLC, Elkhart, IN) is a new blood glucose (BG) monitoring system (BGMS) that uses glucose dehydrogenase chemistry and that combines low sample volume, fast response time, an auto-control marking feature, and an auto-calibration function in a small package. METHOD...

journal_title：Diabetes technology & therapeutics

authors： Kilo C,Pinson M,Joynes JO,Joseph H,Monhaut N,Parkes JL,Baum J

更新日期：2005-04-01 00:00:00

abstract：:Although hypodermic needles rapidly deliver large doses of drugs such as insulin across the skin for systemic administration, the pain, local trauma, and difficulty to achieve sustained or complex delivery profiles has motivated development of novel alternative technologies. Microneedles, jet injectors, and thermal po...

journal_title：Diabetes technology & therapeutics

authors： Prausnitz MR

更新日期：2001-07-01 00:00:00

abstract：:The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor isoforms, including PPARgamma, PPARalpha, and PPARdelta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. P...

journal_title：Diabetes technology & therapeutics

authors： Berger J,Wagner JA

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Internet technology has been proven to be a successful tool for the management of patients with multiple medical conditions. The purpose of this study was to demonstrate the feasibility of monitoring glucose control in indigent women with gestational diabetes mellitus (GDM) over the Internet. METHODS:Women ...

journal_title：Diabetes technology & therapeutics

authors： Homko CJ,Santamore WP,Whiteman V,Bower M,Berger P,Geifman-Holtzman O,Bove AA

更新日期：2007-06-01 00:00:00